TYR and Alzheimer disease: Despite the participants from the ADNI cohort being huge, we restricted the patient inclusion to those we had results for CSF, plasma, and neuroimaging ATN biomarkers, which limited the sample size of the results and required validation in other cohorts, which may prove useful for the future prediction and diagnosis of AD.